Categories AlphaGraphs, Health Care, U.S. Markets News

Allergan, Mylan and other generics beam as Pfizer loses patent war in the UK

It was good news for generic drug firms such as Allergan (AGN) and Mylan (MYL), as pharma giant Pfizer (PFE) lost a long legal battle in Britain regarding the patents surrounding its hit drug Lyrica.

Pain drug Lyrica — generically: pregabalin — rakes in about $5 billion a year for the drugmaker, and the UK apex court ruled against Pfizer affirming a secondary medical use for the medication.

Years of legal bouts in lower courts finally ended with a defeat, and it is more significant now that the secondary pain patent has expired in Europe.

Pfizer, expressing disappointment at the ruling, said that the outcome was a huge blow to medical innovation incentives.

Pfizer third quarter 2018 Earnings Infographic

Pfizer argued that generic drug companies such as Actavis (now, Allergen) and Mylan would be subject to patent infringement on the second patent, despite skinny labeling (generic products labeled only as suitable for treatment of epilepsy and GAD.)

The Supreme Court said it saw Pfizer claims failing “for insufficiency” and overruled the patent plea.

In a gist, the ruling suggests that the patent protection for manufacturing pregabalin — to treat peripheral and central neuropathic pain — was removed.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Infographic: How UnitedHealth Group (UNH) performed in Q2 2024

UnitedHealth Group (NYSE: UNH) reported second quarter 2024 earnings results today. Revenues increased to $98.9 billion from $92.9 billion a year ago. Net earnings attributable to UnitedHealth Group common shareholders

SCHW Earnings: Highlights of Charles Schwab Corporation’s Q2 2024 results

Financial services company The Charles Schwab Corporation (NYSE: SCHW) on Tuesday reported a decrease in adjusted earnings and a modest increase in revenues for the second quarter of 2024. Total

BAC Earnings: Key quarterly highlights from Bank of America’s Q2 2024 financial results

Bank of America (NYSE: BAC) reported its second quarter 2024 earnings results today. Revenue, net of interest expense, of $25.4 billion increased 1% from the prior-year period, reflecting higher asset

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top